MARKET

TECH

TECH

Bio-Techne
NASDAQ

Real-time Quotes | Nasdaq Last Sale

361.24
-14.20
-3.78%
After Hours: 361.24 0 0.00% 16:42 03/03 EST
OPEN
372.15
PREV CLOSE
375.44
HIGH
372.32
LOW
361.10
VOLUME
162.60K
TURNOVER
--
52 WEEK HIGH
414.99
52 WEEK LOW
155.17
MARKET CAP
14.02B
P/E (TTM)
82.33
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Bio-Techne to Acquire Asuragen For Initial $215 million Cash Consideration
MT Newswires · 5h ago
Global Led Temperature Regulators Market Size 2021 By Emerging Trends, Industry Share, Growth Strategy, Developing Technologies, Market Potential, Traders, Regional Overview and SWOT Analysis till 2026
The Express Wire · 17h ago
Global Hollow Blow Molding Machine Market 2020 Industry Outlook, Key Players, Segmentation Analysis, Business Growth and Forecast to 2025
Mar 02, 2021 (CDN Newswire via Comtex) -- Global Hollow Blow Molding Machine Market Growth 2020-2025 aims to fill the need of organizations of settling on...
CDN Newswire · 1d ago
RenalytixAI Reports Financial Results for Second Quarter of Fiscal Year 2021
NEW YORK, March 02, Mar 02, 2021 (GLOBE NEWSWIRE via COMTEX) -- NEW YORK, March 02, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX)...
GlobeNewswire · 1d ago
Bio-Techne To Present At The Barclays Global Healthcare Conference
, /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that , President and Chief Executive Officer, will present at the Barclays Global Healthcare Conference on at . A live webcast of the presentation can be accessed via the IR Calendar...
PR Newswire - PRF · 1d ago
Bio-Techne's Exosome Diagnostics Laboratory Announces Reimbursement Contract With Humana Covering Its ExoDx Prostate Prostate Test
MINNEAPOLIS, March 1, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Humana has awarded a contract effective April 1, 2021 to its Exosome Diagnostics laboratory,
Benzinga · 2d ago
Bio-Techne's Exosome Diagnostics Laboratory Announces Reimbursement Contract With Humana
, /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Humana has awarded a contract effective to its Exosome Diagnostics laboratory, covering the ExoDx™ Prostate (EPI) test for men. Humana is the nation's largest Medicare Advantage ...
PR Newswire - PRF · 2d ago
Global Green Tea Market Size & Share Will Reach USD 20,000 Million By 2026: Facts & Factors
Facts and Factors have published a new research report titled "Green Tea Market By Type (Iced Green Tea, Green Tea Bags, Loose-Leaf, Green Tea Instant Mixes, and Others), By Flavor (Basil, Lemon, Cinnamon, Aloe Vera, Vanilla, and Others), By Distributio...
GlobeNewswire · 5d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TECH. Analyze the recent business situations of Bio-Techne through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TECH stock price target is 411.67 with a high estimate of 465.00 and a low estimate of 365.00.
EPS
Institutional Holdings
Institutions: 617
Institutional Holdings: 39.30M
% Owned: 101.29%
Shares Outstanding: 38.80M
TypeInstitutionsShares
Increased
149
1.09M
New
101
845.49K
Decreased
142
2.16M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.96%
Pharmaceuticals & Medical Research
-1.89%
Key Executives
Chairman/Independent Director
Robert Baumgartner
President/Chief Executive Officer/Director
Charles Kummeth
Chief Financial Officer/Executive Vice President - Finance
James Hippel
Corporate Executive
David Eansor
Corporate Executive
Kim Kelderman
Senior Vice President/General Counsel/Secretary
Brenda Furlow
Independent Director
Julie Bushman
Independent Director
John Higgins
Independent Director
Joseph Keegan
Independent Director
Roeland Nusse
Independent Director
Alpna Seth
Independent Director
Randolph Steer
Independent Director
Rupert Vessey
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
02/02/2021
Dividend USD 0.32
02/11/2021
11/05/2020
Dividend USD 0.32
11/13/2020
08/04/2020
Dividend USD 0.32
08/17/2020
04/30/2020
Dividend USD 0.32
05/08/2020
02/04/2020
Dividend USD 0.32
02/13/2020
10/29/2019
Dividend USD 0.32
11/07/2019
08/06/2019
Dividend USD 0.32
08/15/2019
04/30/2019
Dividend USD 0.32
05/09/2019
02/05/2019
Dividend USD 0.32
02/14/2019
--
Dividend USD 0.32
11/08/2018
--
Dividend USD 0.32
08/16/2018
--
Dividend USD 0.32
05/11/2018
--
Dividend USD 0.32
02/15/2018
--
Dividend USD 0.32
11/09/2017
--
Dividend USD 0.32
08/16/2017
--
Dividend USD 0.32
05/17/2017
--
Dividend USD 0.32
02/15/2017
10/31/2016
Dividend USD 0.32
11/09/2016
08/17/2016
Dividend USD 0.32
08/25/2016
04/26/2016
Dividend USD 0.32
05/11/2016
--
Dividend USD 0.32
02/10/2016
--
Dividend USD 0.32
11/10/2015
08/06/2015
Dividend USD 0.32
08/13/2015
05/05/2015
Dividend USD 0.32
05/13/2015
02/03/2015
Dividend USD 0.32
02/11/2015
10/30/2014
Dividend USD 0.32
11/06/2014
08/11/2014
Dividend USD 0.31
08/19/2014
04/28/2014
Dividend USD 0.31
05/07/2014
02/04/2013
Dividend USD 0.31
02/12/2014
10/31/2013
Dividend USD 0.31
11/07/2013
08/06/2013
Dividend USD 0.3
08/14/2013
04/30/2013
Dividend USD 0.3
05/08/2013
02/05/2013
Dividend USD 0.3
02/13/2013
10/26/2012
Dividend USD 0.3
11/01/2012
07/31/2012
Dividend USD 0.28
08/08/2012
05/01/2012
Dividend USD 0.28
05/09/2012
01/31/2012
Dividend USD 0.28
02/08/2012
10/27/2011
Dividend USD 0.28
11/03/2011
08/02/2011
Dividend USD 0.27
08/10/2011
05/03/2011
Dividend USD 0.27
05/11/2011
02/01/2011
Dividend USD 0.27
02/09/2011
10/28/2010
Dividend USD 0.27
11/04/2010
--
Dividend USD 0.26
08/12/2010
05/04/2010
Dividend USD 0.26
05/12/2010
02/02/2010
Dividend USD 0.26
02/10/2010
10/29/2009
Dividend USD 0.26
11/05/2009
08/04/2009
Dividend USD 0.25
08/13/2009
04/28/2009
Dividend USD 0.25
05/06/2009
02/03/2009
Dividend USD 0.25
02/11/2009
10/23/2008
Dividend USD 0.25
10/30/2008
More
About TECH
Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through two segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences reporting segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biotechnology community. The Protein Sciences segment also provides an array of platforms useful in various areas of protein analysis. The Diagnostics and Genomics reporting segment provides blood chemistry and blood gas quality controls, hematology instrument controls, diagnostics immunoassays and other bulk and custom reagents for the in vitro diagnostic market.

Webull offers kinds of BIO-TECHNE Corp stock information, including NASDAQ:TECH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TECH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TECH stock methods without spending real money on the virtual paper trading platform.